Brief: Arvinas Announces FDA Acceptance Of The New Drug Application

Arvinas

08/08/2025 23:17

Aug 8 (Reuters) - Arvinas Inc ARVN.O:

ARVINAS ANNOUNCES FDA ACCEPTANCE OF THE NEW DRUG APPLICATION FOR VEPDEGESTRANT FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED BREAST CANCER

ARVINAS INC - FDA ASSIGNS PDUFA ACTION DATE OF JUNE 5, 2026

ARVINAS INC - VEPDEGESTRANT GRANTED FAST TRACK DESIGNATION BY FDA

Source text: ID:nGNX8J4zbW

Further company coverage: ARVN.O

 ((Reuters.Briefs@thomsonreuters.com;))